key: cord-1017871-17o8agi1
authors: Ahmad, Shahzaib; Yasin, Fatima; Pustake, Manas; Khan, Hadin Darain; Correia, Inês F Silva
title: The current dengue outbreak amidst COVID-19 pandemic in Pakistan; a major threat to Pakistan’s healthcare system
date: 2022-05-02
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103670
sha: 04ed035df17e50395cc658bf7673d28a0db4b318
doc_id: 1017871
cord_uid: 17o8agi1

nan

Dear Editor, Pakistan is facing another calamity in the form of a Dengue outbreak which has been surging since the advent of October 2021. Public and private hospitals in the federal capital Islamabad and other cities of Pakistan are under a great burden as this outbreak has struck amidst the COVID-19 pandemic. The situation has become alarming with the recent Dengue surge diverting attention from the COVID-19 pandemic and authorities failing to compile data, resulting in underreporting of cases. The immediate anti-dengue surveillance campaign has shown many hotspots where the Dengue vector is breeding continuously, and an anti-dengue campaign has been launched in the capital as well as in other provinces to cater to this issue. However, underreporting and a deficiency in surveillance are aggravating the problem. (1) The target of this letter is to highlight this under-reporting and surveillance issue so that the proper interventions can be made for better protection of the population at risk from this lethal outbreak. Moreover, the global attraction to the problem is aimed at preventing its application elsewhere.

Dengue is an infectious disease caused by any of the four virus serotypes: DENVs. (2) (3) (4) (5) It is a mosquito-borne disease and is primarily transmitted to humans by the female Aedes mosquito. It is a daytime breeder, biting the victim early in the morning or just before dark and spreading quickly, with the victim developing a viremia after just 4 days of being bitten by an infected mosquito. The fever arises and subsides in a cyclical pattern and the victim's platelet count starts decreasing. The disease is mainly concentrated in tropical and subtropical regions, putting nearly a third of the human population, worldwide, at risk of infection. Infection with DENV results in varying degrees of pathological conditions, ranging from mild asymptomatic Dengue fever (DF) to severe Dengue hemorrhagic fever (DHF) and Dengue shock syndrome (DSS) which may be fatal. A dramatic worldwide expansion of the DENV has occurred due to rapid urbanisation, an increase in international travel, a lack of effective mosquito control measures and globalisation. Though there is no approved drug, an update by Sanofi Pasteur reveals licensing of its vaccine in Mexico, Brazil, the Philippines and El Salvador. (3) Dengue has been a problem for Pakistan for many years, having faced its first outbreak in 1994 and a sudden increase in human cases in October 2005. Dengue is now an epidemic in Pakistan and many outbreaks have been reported in 2010, 2017, 2019 and 2020. Cases of Dengue fever circulate throughout the year, with a peak incidence occurring in the monsoon season. The 2020 outbreak was amidst a COVID-19 pandemic that resulted in about 3,442 human cases of Dengue fever, leading to a significant threat to Pakistan's healthcare system. Furthermore, the country is now facing another dangerous outbreak of Dengue fever amidst the COVID-19 pandemic. (8) The National Institute of Health (NIH) of Islamabad, Pakistan, has published a report at the end of October 2021 in which it was said there were 25,478 cases of Dengue fever so far this year, with an escalation of almost 22,000 cases in just the past two months. (1) The challenges in combating the Dengue epidemic are many, including limited economic resources, lack of awareness, education, or action, limited community cohesion, limited sustainability of government interventions and an ineffective reporting system and surveillance. A complex combination of economic, environmental, health, political, and social factors can influence an individual's and community's adherence to suggested Dengue prevention strategies, either directly or indirectly. (9). Pakistan's Emergency Plan of Action (EPoA): Dengue Response is currently being enacted to curtail Dengue vector control. This project aims to limit the spread of vector transmission and develop prevention measures among vulnerable groups by providing long-lasting insecticidal nets (LLINs), mosquito repellent, spraying and fumigating mosquito breeding areas while raising community and educational awareness. (10) It is critical that the government investigates the problem before it escalates into a more dangerous situation for these communities, as well as committing adequate funding for preventative measures. Furthermore, an effective system for formal case reports should be in place so that the exact gravity of the situation can be determined quickly. By understanding how these intrinsic and extrinsic factors hinder adherence, health authorities can adopt national policies to strengthen community participatory action in vector control, empower leadership potential among health workers and community members and provide an appropriate and systemic approach to preventing disease transmission. A plan should be fully implemented, and the reaction to the program, as well as beneficiary input, should be analyzed and monitored. The public should be appropriately informed about current and previous epidemics so that they can play an important part in preventing future outbreaks, such as understanding how to seek medical treatment following a fever and avoid aspirin and ibuprofen if sick. Furthermore, the municipality should take proactive measures to keep public spaces and hospitals as clean as possible, while the community is taught on proper waste disposal and the dangers that can result if it is not done. Sources of stagnant water should also be discarded and avoided in order to eliminate the vector's reproductive grounds. All of these methods necessitate community involvement in order for a Dengue awareness program to function effectively through intersectoral coordination. The seriousness of the situation has been explained, and this letter is intended to draw the government's attention to the problem while it is still in its early stages. The impact on the health system is significant as the number of severe illnesses rises and more individuals require rapid hospitalization. To protect Pakistan's communities from a future outbreak, guidelines and effective control procedures should be implemented.

Surveillance of intensity level and geographical spreading of dengue outbreak among males and females in Punjab, Pakistan: A case study of 2011

Clinical features of covid-19

Streptococcus agalactiae in adults at Chiang Mai University Hospital: a retrospective study

Denguefieber : Klinik, Epidemiologie, Entomologie, Erregerdiagnostik und Prävention

Dengue vaccine acceptance and willingness to pay

COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes

Dengue: A Minireview. Viruses

Challenges & options in dengue prevention & control: A perspective from the 2015 outbreak

Dengue Response Emergency Plan of Action (EPoA) DREF Operation n° MDRPK022 -Pakistan

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.Every author contributed to every stage of paper writing and design J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:

Unique Identifying number or registration ID:

Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Fatima Yasin yasinfatima18@gmail.com